Delaware |
3359 |
85-3174357 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification No.) |
Edward J. Hejlek Chief Legal Officer, General Counsel and Secretary Enovix Corporation 3501 W. Warren Avenue Fremont, CA 94538 Telephone: (510) 695-2350 |
Matthew B. Hemington John T. McKenna Miguel J. Vega Cooley LLP 3175 Hanover Street Palo Alto, CA 94304 Telephone: (650) 843-5000 Fax: (650) 849-7400 |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
• |
up to 66,655,781 shares of Common Stock consisting of |
• |
up to 12,500,000 shares of Common Stock issued in a private placement pursuant to subscription agreements (“ Subscription Agreements |
• |
up to 6,000,000 shares of Common Stock issuable upon exercise of the Private Placement Warrants, |
• |
up to 736,769 shares of Common Stock issuable upon the exercise of stock options, |
• |
up to 5,750,000 shares of Common Stock issued pursuant to that certain Subscription Agreement, dated September 24, 2020, by and between the Company and the Sponsor, and |
• |
up to 41,669,012 shares of Common Stock issued pursuant to that certain Agreement and Plan of Merger, dated as of February 22, 2021, by and among the Company, RSVAC Merger Sub Inc. and Enovix Operations Inc. (f/k/a Enovix Corporation) and subject to that certain Amended and Restated Registration Rights Agreement, dated July 14, 2021, between us and certain Selling Securityholders granting such holders registration rights with respect to such shares, and |
• |
up to 6,000,000 Private Placement Warrants. We will not receive any proceeds from the sale of shares of Common Stock or Private Placement Warrants by the Selling Securityholders pursuant to this prospectus. |
Page |
||||
1 | ||||
7 | ||||
28 | ||||
28 | ||||
28 | ||||
28 | ||||
29 | ||||
45 | ||||
46 | ||||
58 | ||||
67 | ||||
81 | ||||
86 | ||||
88 | ||||
96 | ||||
103 | ||||
109 | ||||
112 | ||||
112 | ||||
112 | ||||
F-1 |
||||
F-17 |
• | our ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition and the ability of the combined business to grow and manage growth profitably; |
• | costs related to the Business Combination; |
• | our financial and business performance; |
• | our service revenue and projections thereof; |
• | our ability to convert our revenue funnel to purchase orders and revenue; |
• | changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; |
• | the future demand for lithium-ion battery solutions; |
• | our ability to meet the expectations of new and current customers; |
• | our ability to achieve broader market acceptance for our products; |
• | the effect of the coronavirus (“ COVID-19 |
• | changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; |
• | our ability to meet milestones and deliver on our objectives and expectations, the implementation, market acceptance and success of our business model and growth strategy, various addressable markets, market opportunity and the expansion of our customer base; |
• | our ability to build and scale our advanced silicon-anode lithium-ion battery, our production and commercialization timeline |
• | our placement of equipment orders for our next-generation manufacturing line, the speed of and space requirements for our next-generation manufacturing line relative to our existing lines at Fab-1 in Fremont; |
• | our ability to attract and hire additional service providers, the strength of our brand, the build out of additional production lines, our ability to optimize our manufacturing process, our future product development and roadmap; |
• | our ability to raise capital; |
• | developments and projections relating to our competitors and industry; |
• | the impact of government laws and regulations and liabilities thereunder; |
• | the outcome of any known and unknown litigation and regulatory proceedings; and |
• | other risks and uncertainties set forth in the section titled “ Risk Factors |
• | We will need to improve our energy density, which requires us to implement higher energy density materials for both cathodes and anodes, which we may not be able to do. |
• | We rely on a new and complex manufacturing process for our operations: achieving production involves a significant degree of risk and uncertainty in terms of operational performance and costs. |
• | We currently do not have manufacturing facilities to produce our lithium-ion battery cell in sufficient quantities to meet expected demand, and if we cannot successfully locate and bring an additional facility online, our business will be negatively impacted and could fail. |
• | We may not be able to source or establish supply relationships for necessary components or may be required to pay costs for components that are more expensive than anticipated, which could delay the introduction of our product and negatively impact our business. |
• | We may be unable to adequately control the costs associated with our operations and the components necessary to build our lithium-ion battery cells. |
• | If our batteries fail to perform as expected, our ability to develop, market and sell our batteries could be harmed. |
• | Operational problems with our manufacturing equipment subject us to safety risks which, if not adequately addressed, could have a material adverse effect on our business, results of operations, cash flows, financial condition or prospects. |
• | The battery market continues to evolve and is highly competitive, and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers. |
• | If we are unable to attract and retain key employees and qualified personnel, our ability to compete could be harmed. |
• | We are an early-stage company with a history of financial losses and expect to incur significant expenses and continuing losses for the foreseeable future. |
• | We may become subject to product liability claims, which could harm our financial condition and liquidity if we are not able to successfully defend or insure against such claims. |
• | We have been, and may in the future be, adversely affected by the global COVID-19 pandemic. |
• | We may not have adequate funds to acquire our next manufacturing facility and build it out, and may need to raise additional capital, which we may not be able to do. |
• | We rely heavily on our intellectual property portfolio. If we are unable to protect our intellectual property rights, our business and competitive position would be harmed. |
• | We could face state-sponsored competition from overseas and may not be able to compete in the market on the basis of price. |
• | In the past, we have identified material weaknesses in our internal control over financial reporting. If we are unable to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and stock price. |
Shares of Common Stock offered by us |
6,000,000 shares of Common Stock issuable upon the exercise of 6,000,000 Private Placement Warrants. |
Shares of Common Stock outstanding prior to exercise of all Warrants |
145,245,628 shares (as of July 14, 2021). |
Shares of Common Stock outstanding assuming exercise of all Warrants |
162,745,628 shares (based on total shares outstanding as of July 14, 2021). |
Exercise price of Warrants |
$11.50 per share, subject to adjustment as described herein. |
Use of proceeds |
We will receive up to an aggregate of approximately $69.0 million from the exercise of the Private Placement Warrants, assuming the exercise in full of all of the Private Placement Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. See the section titled “ Use of Proceeds |
Shares of Common Stock offered by the Selling Securityholders |
We are registering the resale by the Selling Securityholders named in this prospectus, or their permitted transferees, and aggregate of 66,655,781 shares of Common Stock, consisting of: |
• | up to 12,500,000 PIPE Shares; |
• | up to 5,750,000 Founder Shares; |
• | up to 6,000,000 shares of Common Stock issuable upon the exercise of the Private Placement Warrants; |
• | up to 736,769 shares of Common Stock issuable upon the exercise of stock options; and |
• | up to 41,669,012 shares of Common Stock pursuant to the Registration Rights Agreement. |
Private Placement Warrants offered by the Selling Securityholders |
Up to 6,000,000 of Private Placement Warrants. |
Redemption |
The Private Placement Warrants are redeemable in certain circumstances. See the section titled “ Description of Our Securities — Warrants. |
Terms of the offering |
The Selling Securityholders will determine when and how they will dispose of the securities registered for resale under this prospectus. |
Use of proceeds |
We will not receive any proceeds from the sale of shares of Common Stock or Private Placement Warrants by the Selling Securityholders. |
Risk factors |
Before investing in our securities, you should carefully read and consider the information set forth in the section titled “” beginning on page 7. |
Nasdaq ticker symbol |
“ENVX” |
• | our ability and the cost to develop our new and complex manufacturing process that will produce lithium-ion batteries in a cost-effective manner; |
• | our ability to bring our Fremont manufacturing facility online in a timely and cost-effective manner; |
• | our ability to locate and acquire a new, larger manufacturing facility on commercially reasonable terms; |
• | our ability to build out our new, larger manufacturing facility in a cost-effective manner; |
• | the cost of preparing to manufacture lithium-ion batteries on a larger scale; |
• | the costs of commercialization activities including product sales, marketing, manufacturing and distribution; |
• | our ability to hire additional personnel; |
• | the demand for our lithium-ion batteries and the prices for which we will be able to sell our lithium-ion batteries; |
• | the emergence of competing technologies or other adverse market developments; |
• | the effects of the COVID-19 pandemic on our business, results of operations and financial condition; and |
• | volatility in the equity markets, including as a result of war or other armed conflict, such as Russia’s invasion of Ukraine. |
• | cease selling, incorporating or using products that incorporate the challenged intellectual property; |
• | pay substantial damages; |
• | obtain a license from the holder of the infringed intellectual property right, which license may not be available on reasonable terms or at all; or |
• | redesign our batteries. |
• | actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; |
• | changes in the market’s expectations about our operating results; |
• | success of competitors; |
• | our operating results failing to meet the expectation of securities analysts or investors in a particular period; |
• | changes in financial estimates and recommendations by securities analysts concerning us or the market in general; |
• | operating and stock price performance of other companies that investors deem comparable to us; |
• | our ability to develop product candidates; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation involving us; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of shares of our securities available for public sale; |
• | any major change in our board of directors or management; |
• | sales of substantial amounts of Common Stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and |
• | general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or other armed conflict or terrorism. |
• | a limited availability of market quotations for our securities; |
• | a determination that our Common Stock is a “penny stock” which will require brokers trading in our Common Stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our Common Stock; |
• | a limited amount of analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | any derivative action or proceeding brought on our behalf; |
• | any action asserting a claim of breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; |
• | any action asserting a claim against us by any of our current or former directors, officers or other employees to us or our stockholders arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; |
• | any action or proceeding to interpret, apply, enforce or determine the validity of the amended and restated certificate of incorporation or the amended or restated bylaws (including any right, obligation or remedy thereunder); |
• | any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and |
• | any action asserting a claim against us or any of our current or former directors, officers or other employees that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants. |
• | We produced advanced 3D Silicon TM lithium-ion batteries for customers from our first production line for customer qualification. By moving into production in the wearable category, we expect to recognize our first product revenue in the second quarter of 2022. |
• | We announced BrakeFlow TM , a breakthrough in advanced lithium-ion battery safety. This critical innovation was possible due to our unique battery architecture, and we believe it puts considerable distance between us and any competitor that plans to meaningfully increase the energy in its batteries. |
• | Engaged Opportunities: Consists of engaged customers that have determined that our battery is applicable to their product and are evaluating our technology. |
• | Active Designs: Consists of customers that have completed evaluation of our technology, identified the end-product and started design work. |
• | Design Win: Consists of customers that have funded a custom battery design or are qualifying one of our standard batteries for a formally approved product that will use an Enovix cell. |
For the Quarters Ended |
||||||||||||||||
April 3, 2022 |
March 31, 2021 |
Change ($) |
% Change |
|||||||||||||
Operating expenses: |
||||||||||||||||
Cost of revenue |
$ | 515 | $ | 1,631 | $ | (1,116 | ) | (68 | %) | |||||||
Research and development |
12,731 | 5,589 | 7,142 | 128 | % | |||||||||||
Selling, general and administrative |
11,869 | 4,161 | 7,708 | 185 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
25,115 | 11,381 | 13,734 | 121 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Loss from operations |
(25,115 | ) | (11,381 | ) | (13,734 | ) | 121 | % | ||||||||
Other income (expense): |
||||||||||||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
67,800 | (4,781 | ) | 72,581 | N/M | |||||||||||
Other income (expense), net |
22 | (3 | ) | 25 | N/M | |||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense), net |
67,822 | (4,784 | ) | 72,606 | N/M | |||||||||||
|
|
|
|
|
|
|||||||||||
Net income (loss) |
$ | 42,707 | $ | (16,165 | ) | $ | 58,872 | (364 | %) | |||||||
|
|
|
|
|
|
Fiscal Years |
||||||||||||||||
2021 |
2020 |
Change ($) |
% Change |
|||||||||||||
Operating expenses: |
||||||||||||||||
Cost of revenue |
$ | 1,967 | $ | 3,375 | $ | (1,408 | ) | (42 | %) | |||||||
Research and development |
37,850 | 14,442 | 23,408 | 162 | % | |||||||||||
Selling, general and administrative |
29,705 | 5,713 | 23,992 | 420 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
69,522 | 23,530 | 45,992 | 195 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Loss from operations |
(69,522 | ) | (23,530 | ) | (45,992 | ) | 195 | % | ||||||||
Other income (expense): |
||||||||||||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
(56,141 | ) | (13,789 | ) | (42,352 | ) | 307 | % | ||||||||
Issuance of convertible preferred stock warrants |
— | (1,476 | ) | 1,476 | N/M | |||||||||||
Change in fair value of convertible promissory notes |
— | (2,422 | ) | 2,422 | N/M | |||||||||||
Gain on extinguishment of paycheck protection program loan |
— | 1,628 | (1,628 | ) | N/M | |||||||||||
Interest expense, net |
(187 | ) | (107 | ) | (80 | ) | 75 | % | ||||||||
Other income (expense), net |
(24 | ) | 46 | (70 | ) | N/M | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other expense, net |
(56,352 | ) | (16,120 | ) | (40,232 | ) | 250 | % | ||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (125,874 | ) | $ | (39,650 | ) | $ | (86,224 | ) | 217 | % | |||||
|
|
|
|
|
|
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Net income (loss) |
$ | 42,707 | $ | (16,165 | ) | |||
Depreciation and amortization |
448 | 141 | ||||||
|
|
|
|
|||||
EBITDA |
43,155 | (16,024 | ) | |||||
Stock-based compensation expense |
5,238 | 1,418 | ||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
(67,800 | ) | 4,781 | |||||
|
|
|
|
|||||
Adjusted EBITDA |
$ | (19,407 | ) | $ | (9,825 | ) | ||
|
|
|
|
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Net loss |
$ | (125,874 | ) | $ | (39,650 | ) | ||
Interest expense, net |
187 | 107 | ||||||
Depreciation and amortization |
1,515 | 579 | ||||||
|
|
|
|
|||||
EBITDA |
(124,172 | ) | (38,964 | ) | ||||
Stock-based compensation |
10,711 | 666 | ||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
56,141 | 13,789 | ||||||
Issuance of convertible preferred stock warrants |
— | 1,476 | ||||||
Change in fair value of convertible promissory notes |
— | 2,422 | ||||||
Loss (gain) on early debt extinguishment |
60 | (1,628 | ) | |||||
|
|
|
|
|||||
Adjusted EBITDA |
$ | (57,260 | ) | $ | (22,239 | ) | ||
|
|
|
|
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Net cash used in operating activities |
$ | (19,689 | ) | $ | (8,610 | ) | ||
Capital expenditures |
(10,451 | ) | (7,141 | ) | ||||
|
|
|
|
|||||
Free Cash Flow |
$ | (30,140 | ) | $ | (15,751 | ) | ||
|
|
|
|
|||||
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Net cash used in operating activities |
$ | (51,306 | ) | $ | (20,050 | ) | ||
Capital expenditures |
(43,584 | ) | (26,953 | ) | ||||
|
|
|
|
|||||
Free Cash Flow |
$ | (94,890 | ) | $ | (47,003 | ) | ||
|
|
|
|
For the Quarters Ended |
||||||||||||
April 3, 2022 |
March 31, 2021 |
Change ($) |
||||||||||
Net cash used in operating activities |
$ | (19,689 | ) | $ | (8,610 | ) | $ | (11,079 | ) | |||
Net cash used in investing activities |
(10,451 | ) | (7,141 | ) | (3,310 | ) | ||||||
Net cash provided by (used in) financing activities |
53,025 | (76 | ) | 53,101 | ||||||||
|
|
|
|
|
|
|||||||
Change in cash, cash equivalents and restricted cash |
$ | 22,885 | $ | (15,827 | ) | $ | 38,712 | |||||
|
|
|
|
|
|
|||||||
Fiscal Years |
||||||||||||
2021 |
2020 |
Change ($) |
||||||||||
Net cash used in operating activities |
$ | (51,306 | ) | $ | (20,050 | ) | $ | (31,256 | ) | |||
Net cash used in investing activities |
(43,584 | ) | (26,953 | ) | (16,631 | ) | ||||||
Net cash provided by financing activities |
451,090 | 65,920 | 385,170 | |||||||||
|
|
|
|
|
|
|||||||
Change in cash, cash equivalents and restricted cash |
$ | 356,200 | $ | 18,917 | $ | 337,283 | ||||||
|
|
|
|
|
|
• | identification of the contract, or contracts, with a customer; |
• | identification of the performance obligations in the contract; |
• | determination of the transaction price; |
• | allocation of the transaction price to the performance obligations in the contract; and |
• | recognition of revenue when, or as, we satisfy a performance obligation. |
• | The grant date fair value of RSUs is the last reported sales price of our Common Stock on the grant date. |
• | The fair value of shares to be purchased under the ESPP (as defined in the section titled “ Executive Compensation — Employee Benefit Plans |
• | The fair value of stock options is based on the grant date fair value using the Black-Scholes option pricing model with several significant assumptions and estimates, including the grant date fair value of Legacy Enovix common stock prior to the Business Combination, our stock price volatility, expected life and others. |
• | Formation expansion. |
• | Formation efficiency. |
• | Cycle swelling. |
• | Cycle life. |
• | Integrity |
• | Respect |
• | Innovation |
• | Resilience |
• | Excellence |
• | Customer Focus |
Name |
Age |
Position(s) | ||||
Harrold J. Rust |
60 | President and Chief Executive Officer and Director | ||||
Ashok Lahiri |
61 | Chief Technology Officer | ||||
Steffen Pietzke |
50 | Chief Financial Officer | ||||
Cameron Dales |
51 | Chief Commercial Officer | ||||
Edward J. Hejlek |
66 | Chief Legal Officer, General Counsel and Secretary | ||||
Thurman J. “T.J.” Rodgers |
74 | Chairman of the Board of Directors | ||||
Betsy Atkins (1)(2) |
68 | Director | ||||
Pegah Ebrahimi (2)(3) |
42 | Director | ||||
Emmanuel T. Hernandez (3) |
66 | Director | ||||
John D. McCranie (1)(3) |
78 | Director | ||||
Gregory Reichow (1)(2) |
52 | Director |
(1) | Member of the compensation committee. |
(2) | Member of the nominating and corporate governance committee. |
(3) | Member of the audit committee. |
• | helping the Board of Directors oversee corporate accounting and financial reporting processes; |
• | managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit the financial statements; |
• | discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, the interim and year-end operating results; |
• | reviewing related person transactions; |
• | obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and |
• | approving or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm. |
• | reviewing and approving the compensation of the chief executive officer, other executive officers and senior management; |
• | administering the equity incentive plans and other benefit programs; |
• | reviewing, adopting, amending and terminating incentive compensation and equity plans, employment agreements, severance agreements, profit sharing plans, bonus plans, change-of-control |
• | reviewing and establishing general policies relating to compensation and benefits of the employees, including the overall compensation philosophy. |
• | identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on the Board of Directors; |
• | considering and making recommendations to the Board of Directors regarding the composition and chairpersonship of the committees of the Board of Directors; |
• | reviewing and recommending to the Board of Directors the compensation paid to the directors; |
• | instituting plans or programs for the continuing education of the Board and orientation of new directors; |
• | reviewing, evaluating and recommending to the Board of Directors succession plans for our executive officers; |
• | overseeing our environmental, social and governance activities; |
• | developing and making recommendations to the Board of Directors regarding corporate governance guidelines and matters, including in relation to corporate social responsibility; and |
• | overseeing periodic evaluations of the performance of the Board of Directors, including our individual directors and committees. |
Board of Directors Committee |
Chairperson Fee ($) |
Member Fee ($) |
||||||
Audit Committee |
15,000 | 7,500 | ||||||
Compensation Committee |
10,000 | 5,000 | ||||||
Nominating and Corporate Governance Committee |
10,000 | 5,000 |
Name |
Fees Earned or Paid in Cash ($) |
Stock Awards ($) (1) |
Total ($) (2) |
|||||||||
Thurman J. Rodgers |
35,000 | 56,115 | 91,115 | |||||||||
Betsy Atkins |
30,000 | 56,115 | 86,115 | |||||||||
Pegah Ebrahimi |
9,162 | — | 9,162 | |||||||||
Emmanuel T. Hernandez |
30,000 | 56,115 | 86,115 | |||||||||
John D. McCranie |
28,750 | 56,115 | 84,865 | |||||||||
Michael J. Petrick (3) |
31,250 | 28,057 | 59,307 | |||||||||
Gregory Reichow |
27,500 | 56,115 | 83,615 |
(1) | The amounts reported in this column do not reflect dollar amounts actually received by our non-employee directors. Instead, these amounts reflect the aggregate grant-date fair value of equity awards granted to each non-employee director, computed in accordance with the ASC Topic 718, Stock-based Compensation non-employee directors will only realize compensation to the extent trading price of our common stock is greater than the exercise price of the shares underlying the equity awards. |
(2) | The following table sets forth the aggregate number of units subject to the RSU awards and the aggregate number of shares of our common stock underlying stock options held by each non-employee director as of January 2, 2022. Each unit granted pursuant to an RSU award represents a contingent right to receive one share of our common stock for each unit that vests. |
(3) | Mr. Petrick resigned from our Board of Directors effective November 2021. |
Name |
RSUs |
Number of Shares Underlying Stock Options |
||||||
Thurman J. Rodgers |
2,109 | — | ||||||
Betsy Atkins |
2,109 | 51,691 | ||||||
Pegah Ebrahimi |
13,715 | — | ||||||
Emmanuel T. Hernandez |
2,109 | — | ||||||
John D. McCranie |
2,109 | — | ||||||
Michael J. Petrick (1) |
— | 110,767 | ||||||
Gregory Reichow |
2,109 | — |
(1) | Mr. Petrick resigned from our Board of Directors effective November 2021. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or its stockholders. |
• | attract, incentivize, and retain employees at the executive level who contribute to our long-term success; |
• | provide compensation packages to our executives that are fair and competitive, and that reward the achievement of our business objectives; and |
• | effectively align our executives’ interests with those of our stockholders by focusing on long-term equity incentives that correlate with the creation of long-term value for our stockholders. |
• | Harrold J. Rust, our President and Chief Executive Officer; |
• | Steffen Pietzke, our Chief Financial Officer; and |
• | Ashok Lahiri, our Chief Technology Officer. |
Name and Principal Position |
Fiscal Year |
Salary ($) |
Bonus ($) (1) |
Option Awards ($) (2) |
All Other Compensation ($) (3) |
Total ($) |
||||||||||||||||||
Harrold J. Rust |
2021 | 338,536 | 180,000 | 5,560,515 | 14,605 | 6,093,656 | ||||||||||||||||||
President and Chief Executive Officer |
2020 | 292,868 | — | 1,670,636 | 9,756 | 1,973,260 | ||||||||||||||||||
Steffen Pietzke (4) |
2021 | 224,423 | 78,750 | 2,871,175 | 8,308 | 3,182,656 | ||||||||||||||||||
Chief Financial Officer |
2020 | — | — | — | — | — | ||||||||||||||||||
Ashok Lahiri |
2021 | 308,369 | 73,125 | 586,564 | 11,563 | 979,621 | ||||||||||||||||||
Chief Technology Officer |
2020 | 291,896 | — | 1,670,636 | 9,611 | 1,972,143 |
(1) | The amounts reported in this column represent special bonuses paid to Messrs. Rust, Pietzke and Lahiri representing: (i) one-time discretionary bonuses in the amounts of $120,000, $52,500 and $48,750, respectively, for achievement of the preestablished performance goal of producing the first battery cells on our automated production line, and (ii) one-time discretionary bonuses in the form of fully vested stock options reflecting an aggregate grant date fair value of $60,000, $26,250, and $24,375, respectively. |
(2) | The amounts reported in this column do not reflect dollar amounts actually received by named executive officers. Instead, these amounts reflect the aggregate grant-date fair value of the options to purchase shares of our common stock granted to each named executive officer, computed in accordance with the Financial Accounting Standards Board’s (“ FASB |
(3) | These amounts represent our matching contributions to the 401(k) plan for each named executive officer. For Mr. Rust and Mr. Lahiri, the amounts also include their cell phone expenses. |
(4) | Mr. Pietzke joined Legacy Enovix in April 2021. His annualized base salary as of January 2, 2022 was $350,000. |
Option Awards (1) |
||||||||||||||||||||
Name |
Grant Date |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable (2) |
Option Exercise Price ($) |
Option Expiration Date |
|||||||||||||||
Harrold J. Rust (3) |
12/13/2018 | 24,230 | (4) |
— | 0.05 | 12/13/2027 | ||||||||||||||
President and Chief Executive Officer |
4/20/2021 | 165,438 | (5) |
1,208,395 | (5) |
9.26 | 4/19/2031 | |||||||||||||
Steffen Pietzke Chief Financial Officer |
4/20/2021 | 4,734 | (6) |
712,430 | (6) |
9.26 | 4/19/2031 | |||||||||||||
Ashok Lahiri (7) |
12/13/2018 | 21,538 | (8) |
— | 0.05 | 12/13/2027 | ||||||||||||||
Chief Technology Officer |
4/20/2021 | 9,425 | (9) |
131,951 | (9) |
9.26 | 4/19/2031 |
(1) | All option awards were granted pursuant to our 2016 Equity Incentive Plan, as amended (the “ 2016 Plan |
(2) | Under our 2016 Plan and our 2021 Equity Incentive Plan (the “ 2021 Plan |
(3) | Mr. Rust has 412,295 shares of our common stock subject to repurchase in accordance with our 2016 Plan. |
(4) | For Mr. Rust’s December 13, 2018 grant, the shares of our common stock underlying the option award vests in 48 equal monthly installments beginning on the vesting commencement date, September 1, 2017, subject to the named executive officer’s continued service at each vesting date. |
(5) | For Mr. Rust’s April 20, 2021 grants, they have the following two different vesting terms, and these grants are subject to named executive officer’s continued service at each vesting date. |
a. | 1,107,678 shares of our common stock underlying the option award vests in 60 equal monthly installments beginning on the vesting commencement date, April 18, 2021; and |
b. | 1/120th of the 266,156 shares of our common stock underlying the option award vests in 48 equal monthly installments beginning on the vesting commencement date, April 18, 2021, and 1/20th of the 266,156 shares of our common stock underlying the option award vests in 12 equal monthly installments thereafter. |
(6) | For Mr. Pietzke’s April 20, 2021 grants, they have the following three different vesting terms and these grants are subject to named executive officer’s continued service at each vesting date. |
a. | 1/5th of 276,918 shares of our common stock underlying the option award vests on the one year anniversary of the vesting commencement date, April 18, 2021, and 1/60th of the shares of our common stock underlying the option award vests in 48 equal monthly installments thereafter. |
b. | 1/120th of the 71,020 shares of our common stock underlying the option award vests in 48 equal monthly installments beginning on the vesting commencement date, April 18, 2021, and 1/20th of the shares of our common stock underlying the option award vests in 12 equal monthly installments thereafter; and |
c. | 1/4th of the 369,226 shares of our common stock underlying the option award vests on the one year anniversary of the vesting commencement date, April 1, 2021, and 1/48th of the shares underlying the option award vests in 36 equal monthly installments thereafter. |
(7) | Mr. Lahiri has 408,445 shares of our common stock subject to repurchase in accordance with our 2016 Plan. |
(8) | For Mr. Lahiri’s December 13, 2018 grant, the shares of our common stock underlying the option awards vest in 48 equal monthly installments, subject to the named executive officer’s continued service at each vesting date. |
(9) | For Mr. Lahiri’s April 20, 2021 grant, 1/120th of the 141,376 shares of our common stock underlying the option award vests in 48 equal monthly installments beginning on the vesting commencement date, April 18, 2021, and 1/20th of the shares of our common stock underlying the option award vests in 12 equal monthly installments thereafter, subject to named executive officer’s continued service at each vesting date. |
• | the amounts involved exceeded or will exceed $120,000; and |
• | any of our directors, executive officers or holders of more than 5% of any class of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. |
Name of Noteholder |
Principal Amount of Promissory Notes |
|||
Rodgers Massey Revocable Living Trust dtd 4/4/11 (1) |
$ | 5,000,000 | ||
Michael John Petrick Revocable Trust, as amended (2) |
350,000 | |||
Harrold and Margaret Rust Family Trust UTD May 15, 1996 (3) |
58,392 | |||
Ashok Lahiri (4) |
58,392 |
(1) | Thurman John “TJ” Rodgers was a member of Legacy Enovix’s Board of Directors and is a member of Enovix’s Board of Directors and trustee of the Rodgers Massey Revocable Living Trust dtd 4/4/11. |
(2) | Michael Petrick was a member of Legacy Enovix’s Board of Directors and is a former member of Enovix’s Board of Directors and is a trustee of the Michael John Petrick Revocable Trust, as amended. |
(3) | Harrold Rust was Legacy Enovix’s President, Chief Executive Officer, and a member of Legacy Enovix’s Board of Directors and is Enovix’s President and Chief Executive Officer, a member of Enovix’s Board of Directors, and trustee of the Harrold and Margaret Rust Family Trust UTD May 15, 1996. |
(4) | Ashok Lahiri was Legacy Enovix’s Chief Technology Officer and is Enovix’s Chief Technology Officer. |
Name of Stockholder |
Shares of Legacy Enovix Series F Preferred Stock |
Shares of Legacy Enovix Series P-2 Preferred Stock |
Aggregate Purchase Price |
|||||||||
Rodgers Massey Revocable Living Trust dtd 4/4/11 (1) |
26,877,192 | 23,761,025 | 15,740,327 | |||||||||
Michael John Petrick Revocable Trust, as amended (2) |
5,511,648 | 1,987,571 | 2,276,443 | |||||||||
Harrold and Margaret Rust Family Trust UTD May 15, 1996 (3) |
— | 196,334 | 59,330 | |||||||||
Ashok Lahiri (4) |
— | 196,334 | 59,330 | |||||||||
Eclipse Fund III, L.P. (5) |
— | 13,434,650 | 5,799,725 | |||||||||
DPIP Enovix Series |
8,542,957 | 4,432,036 | 4,348,048 | |||||||||
York Distressed Asset Fund III, L.P |
31,228,069 | 6,949,286 | 11,899,999 |
(1) | Thurman John “TJ” Rodgers was a member of Legacy Enovix’s Board of Directors and is a member of Enovix’s Board of Directors and trustee of the Rodgers Massey Revocable Living Trust dtd 4/4/11. Includes shares of Series P-2 Preferred Stock issued upon the conversion of an unsecured convertible promissory note issued by Legacy Enovix with an aggregate principal amount of $5.0 million. |
(2) | Michael Petrick was a member of Legacy Enovix’s Board of Directors and is a former member of Enovix’s Board of Directors and is a trustee of the Michael John Petrick Revocable Trust, as amended. Includes shares of Series P-2 Preferred Stock issued upon the conversion of an unsecured convertible promissory note issued by Legacy Enovix with an aggregate principal amount of $350,000. |
(3) | Harrold Rust was Legacy Enovix’s President, Chief Executive Officer, and a member of Legacy Enovix’s board of directors and is Enovix’s President, Chief Executive Officer, a member of Enovix’s board of directors, and trustee of the Harrold and Margaret Rust Family Trust UTD May 15, 1996. Includes shares of Series P-2 Preferred Stock issued upon the conversion of an unsecured convertible promissory note issued by Legacy Enovix with an aggregate principal amount of $58,392. |
(4) | Ashok Lahiri was Legacy Enovix’s Chief Technology Officer and is Enovix’s Chief Technology Officer. Includes shares of Series P-2 Preferred Stock issued upon the conversion of an unsecured convertible promissory note issued by Legacy Enovix with an aggregate principal amount of $58,392. |
(5) | Gregory Reichow, a former member of Legacy Enovix’s board of directors and current member of Enovix’s board of directors, is a partner of Eclipse Ventures, an affiliate of Eclipse Fund III, L.P. |
• | the risks, costs, and benefits to us; |
• | the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |
• | the extent of the related person’s interest in the transaction; |
• | the purpose and terms of the transaction; |
• | management’s recommendation with respect to the proposed related person transaction; |
• | the availability of other sources for comparable services or products; and |
• | whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction. |
• | each person known by us to be the beneficial owner of more than 5% of our common stock; |
• | each of our directors and nominees for director; |
• | each of our named executive officers; and |
• | all of our executive officers and directors as a group. |
Beneficial Ownership of Common Stock |
||||||||
Beneficial Owner |
Number of Shares |
Percent of Total |
||||||
Greater Than 5% Stockholder |
||||||||
Eclipse Fund III, L.P. (1) |
17,583,258 | 11.2 | % | |||||
Entities affiliated with Park West Asset Management LLC (2) |
14,786,112 | 9.4 | % | |||||
Named Executive Officers and Directors |
||||||||
Thurman J. Rodgers (3) |
25,144,714 | 15.6 | % | |||||
Betsy Atkins (4) |
340,621 | * | ||||||
Pegah Ebrahimi (5) |
2,135 | * | ||||||
Emmanuel T. Hernandez (6) |
963,162 | * | ||||||
John D. McCranie (7) |
973,162 | * | ||||||
Gregory Reichow (8) |
18,791 | * | ||||||
Harrold J. Rust (9) |
2,788,199 | 1.8 | % | |||||
Ashok Lahiri (10) |
1,522,410 | 1.0 | % | |||||
Steffen Pietzke (11) |
744,406 | * | ||||||
All current directors and executive officers as a group (11 individuals) (12) |
33,909,969 | 20.6 | % |
* | Less than one percent |
(1) | This information is based solely on a Schedule 13G filed with the SEC on July 26, 2021. Consists of 17,583,258 shares of common stock held by Eclipse Fund III, L.P., or Eclipse III. Eclipse GP III, LLC, or Eclipse III GP, is the general partner of Eclipse III and may be deemed to have voting and dispositive power over the shares held by Eclipse III. Lior Susan is the sole managing member of Eclipse III GP and may be deemed to have voting and dispositive power over the shares held by Eclipse III. Eclipse III GP and Mr. Susan disclaim beneficial ownership of the shares held by Eclipse III except to the extent of their pecuniary interest therein, if any. The address for Eclipse III is 514 High Street, Suite 4, Palo Alto, California 94301. |
(2) | Consists of (i) 13,460,906 shares of common stock held by Park West Investors Master Fund, Limited, or PWIMF, and (ii) 1,325,206 shares of common stock held by Park West Partners International, Limited, or PWPI. Park West Asset Management LLC is the investment manager to PWIMF and PWPI, and Peter S. Park, through one or more affiliated entities, is the controlling manager of Park West Asset Management LLC. The business address for Park West Asset Management LLC is 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939. |
(3) | Consists of (i) 3,162 shares of common stock held directly by Mr. Rodgers, (ii) 20,926,552 shares of common stock held by Rodgers Massey Revocable Living Trust dtd 4/4/11, Thurman John Rodgers, Trustee, (iii) 115,000 shares of common stock held by the Sponsor, and (iv) 4,100,000 Private Placement Warrants held by Rodgers Massey Revocable Living Trust dtd 4/4/11, Thurman John Rodgers, Trustee. |
(4) | Consists of (i) 188,930 shares of common stock held directly by Ms. Atkins, of which 71,531 shares of common stock will be unvested and remain subject to a repurchase right within 60 days of April 18, 2022, (ii) 51,691 shares of common stock issuable to Ms. Atkins pursuant to options exercisable within 60 days of April 18, 2022, of which 37,690 shares of common stock would be unvested as of such date, and (iii) 100,000 shares of common stock issuable to Ms. Atkins pursuant to a warrant exercisable within 60 days of April 18, 2022. |
(5) | Consists of 2,135 shares of common stock held directly by Ms. Ebrahimi. |
(6) | Consists of (i) 463,162 shares of common stock held directly by Mr. Hernandez, and (ii) 500,000 shares of common stock issuable to Mr. Hernandez pursuant to a warrant exercisable within 60 days of April 18, 2022. |
(7) | Consists of (i) 473,162 shares of common stock held directly by Mr. McCranie, and (ii) 500,000 shares of common stock issuable to Mr. McCranie pursuant to a warrant exercisable within 60 days of April 18, 2022. |
(8) | Consists of (i) 15,629 shares of common stock held directly by Mr. Reichow, and (ii) 3,162 shares of common stock held by Mr. Reichow for the benefit of Eclipse Ventures, LLC. Mr. Reichow is a Partner of Eclipse Ventures, LLC. Mr. Reichow disclaims beneficial ownership of the shares held for the benefit of Eclipse Ventures, LLC and the shares held by Eclipse III referred to in Footnote 2 above. |
(9) | Consists of (i) 1,379,531 shares of common stock held by the Harrold and Margaret Rust Family Trust UTD May 15, 1996, of which 330,755 shares of common stock will be unvested and remain subject to a repurchase right within 60 days of April 18, 2022, and (ii) 1,408,668 shares of common stock issuable to Mr. Rust pursuant to options exercisable within 60 days of April 18, 2022, of which 1,104,995 shares of common stock would be unvested as of such date. |
(10) | Consists of (i) 1,351,031 shares of common stock held directly by Mr. Lahiri, of which 328,830 shares of common stock will be unvested and remain subject to a repurchase right within 60 days of April 18, 2022, and (ii) 171,379 shares of common stock issuable to Mr. Lahiri pursuant to options exercisable within 60 days of April 18, 2022, of which 126,061 shares of common stock would be unvested as of such date. |
(11) | Consists of (i) 23,000 shares of common stock held directly by Mr. Pietzke, and (ii) 721,406 shares of common stock issuable to Mr. Pietzke pursuant to options exercisable within 60 days of April 18, 2022, of which 541,774 shares of common stock would be unvested as of such date. |
(12) | Consists of (i) 26,094,980 shares of common stock held by all of our directors and executive officers as a group, of which 1,161,868 shares of common stock will be unvested and remain subject to a repurchase right within 60 days of April 18, 2022, and (ii) 2,614,989 shares of common stock issuable pursuant to options exercisable within 60 days of April 18, 2022, of which 2,006,017 shares of common stock would be unvested as of such date. |
Shares of Common Stock |
Warrants to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
||||||||||||||||||||||||
Harrold and Margaret Rust Family Trust UTD May 15, 1996 (1) |
1,376,031 | 1,376,031 | — | — | — | — | — | — | ||||||||||||||||||||||||
Harrold Rust (2) |
334,428 | 334,428 | — | — | — | — | — | — | ||||||||||||||||||||||||
Rodgers Massey Revocable Living Trust dtd 4/4/11, Thurman John Rodgers, Trustee (3) |
20,926,552 | 20,926,552 | — | — | 4,100,000 | 4,100,000 | — | — | ||||||||||||||||||||||||
Rodgers Capital, LLC (4) |
115,000 | 115,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Betsy Atkins (5) |
201,923 | 201,923 | — | — | 100,000 | 100,000 | — | — | ||||||||||||||||||||||||
Emmanuel T. Hernandez (6) |
460,000 | 460,000 | — | — | 500,000 | 500,000 | — | — | ||||||||||||||||||||||||
John D. McCranie (7) |
450,000 | 450,000 | — | — | 500,000 | 500,000 | — | — | ||||||||||||||||||||||||
Michael John Petrick and Leslie Anderson Petrick, as Trustees of the Michael John Petrick Revocable Trust, as amended (8) |
2,958,219 | 2,958,219 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael J. Petrick (9) |
90,004 | 90,004 | — | — | — | — | — | — | ||||||||||||||||||||||||
Gregory Reichow (10) |
15,629 | 15,629 | — | — | — | — | — | — | ||||||||||||||||||||||||
Cameron Dales (11) |
1,016,219 | 1,016,219 | — | — | — | — | — | — | ||||||||||||||||||||||||
Ashok Lahiri (12) |
1,390,240 | 1,390,240 | — | — | — | — | — | — | ||||||||||||||||||||||||
Steffen Pietzke (13) |
195,499 | 195,499 | — | — | 1,000 | — | 1,000 | * | ||||||||||||||||||||||||
Edward J. Hejlek (14) |
192,779 | 192,779 | — | — | — | — | — | — | ||||||||||||||||||||||||
Steven J. Gomo (15) |
295,000 | 295,000 | — | — | 300,000 | 300,000 | — | — | ||||||||||||||||||||||||
Lisan Hung (16) |
262,500 | 262,500 | — | — | 250,000 | 250,000 | — | — | ||||||||||||||||||||||||
Joseph I. Malchow (17) |
262,500 | 262,500 | — | — | 250,000 | 250,000 | — | — | ||||||||||||||||||||||||
Jeff McNeil (18) |
40,000 | 10,000 | 30,000 | * | 15,000 | — | 15,000 | * | ||||||||||||||||||||||||
Mitchell Nussbaum (19) |
10,000 | 10,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Ralph H. Schmitt (20) |
10,000 | 10,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Eclipse Fund III, L.P. (21) |
17,583,258 | 17,583,258 | — | — | — | — | — | — | ||||||||||||||||||||||||
Ardsley Partners Renewable Energy Fund, L.P. (22) |
35,714 | 35,714 | — | — | — | — | — | — | ||||||||||||||||||||||||
Atlas Diversified Master Fund, Ltd. (23) |
285,714 | 285,714 | — | — | — | — | — | — | ||||||||||||||||||||||||
Crossroads Investments, LP (24) |
467,124 | 267,857 | 199,267 | * | — | — | — | — | ||||||||||||||||||||||||
D.E. Shaw Oculus Portfolios, L.L.C. (25) |
89,286 | 89,286 | — | — | — | — | — | — | ||||||||||||||||||||||||
D.E. Shaw Valence Portfolios, L.L.C. (26) |
267,857 | 267,857 | — | — | 145,901 | — | 145,901 | * | ||||||||||||||||||||||||
DG Value Partners, LP (27) |
15,140 | 15,140 | — | — | — | — | — | — | ||||||||||||||||||||||||
DG Value Partners II Master Fund, LP (27) |
83,297 | 83,297 | — | — | — | — | — | — | ||||||||||||||||||||||||
DG Value Partners II Master Fund, LP—Class C (27) |
44,420 | 44,420 | — | — | — | — | — | — | ||||||||||||||||||||||||
AGR Trading SPC-Series EC Segregated Portfolio(28) |
44,054 | 19,058 | 24,996 | * | — | — | — | — | ||||||||||||||||||||||||
Boothbay Absolute Return Strategies, LP (28) |
80,396 | 38,096 | 42,300 | * | — | — | — | — | ||||||||||||||||||||||||
Electron Global Master Fund L.P. (28) |
2,932,802 | 1,195,802 | 1,737,000 | 1.2 | % | — | — | — | — | |||||||||||||||||||||||
Electron Infrastructure Master Fund, L.P. (28) |
2,110,601 | 889,901 | 1,220,700 | * | — | — | — | — | ||||||||||||||||||||||||
PMT Capital, L.P. (29) |
69,847 | 17,857 | 51,990 | — | 25,000 | — | 25,000 | * |
Shares of Common Stock |
Warrants to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
||||||||||||||||||||||||
FT SOF XIII (SPAC) Holdings, LLC (30) |
71,428 | 71,428 | — | — | — | — | — | — | ||||||||||||||||||||||||
Eric S. Stein |
97,000 | 97,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Amanda K. Rieben |
45,857 | 45,857 | — | — | — | — | — | — | ||||||||||||||||||||||||
John M. Stein |
22,857 | 22,857 | — | — | — | — | — | — | ||||||||||||||||||||||||
John M. Stein Roth IRA (31) |
120,000 | 120,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Fort Baker Catalyst Master Fund, LP (32) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
Glazer Capi tal, LLC(33) |
714,286 | 714,286 | — | — | — | — | — | — | ||||||||||||||||||||||||
CVI Investments, Inc. (34) |
357,143 | 357,143 | — | — | 295,933 | — | 295,933 | * | ||||||||||||||||||||||||
Tech Opportunities LLC (35) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
Kepos Alpha Master Fund L.P. (36) |
308,643 | 308,643 | — | — | — | — | — | — | ||||||||||||||||||||||||
Kepos Carbon Transition Master Fund L.P. (36) |
48,500 | 48,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Jon D and Linda W Gruber Trust (37) |
1,233,114 | 35,714 | 1,197,400 | * | — | — | — | — | ||||||||||||||||||||||||
LMR CCSA Master Fund Limited (38) |
71,429 | 71,429 | — | — | — | — | — | — | ||||||||||||||||||||||||
LMR Master Fund Limited (38) |
71,428 | 71,428 | — | — | — | — | — | — | ||||||||||||||||||||||||
Luminus Capital Partners Master Fund, LP (39) |
485,714 | 485,714 | — | — | — | — | — | — | ||||||||||||||||||||||||
Luminus Special Opportunities II Master Fund, Ltd (39) |
85,715 | 85,715 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Constellation Master Fund, Ltd. (40) |
229,286 | 229,286 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Constellation Fund II, Ltd (40) |
64,286 | 64,286 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Structured Credit Fund, LP (40) |
88,571 | 88,571 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Xing He Master Fund Ltd (40) |
79,286 | 79,286 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar SC Fund Ltd (40) |
50,714 | 50,714 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Longhorn Fund LP (40) |
23,571 | 23,571 | — | — | — | — | — | — | ||||||||||||||||||||||||
Purpose Alternative Credit Fund Ltd (40) |
30,000 | 30,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Purpose Alternative Credit Fund – T LLC (40) |
10,000 | 10,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Lake Credit Fund LLC (40) |
31,429 | 31,429 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Capital Master Fund, Ltd (40) |
35,714 | 35,714 | — | — | — | — | — | — | ||||||||||||||||||||||||
Magnetar Discovery Master Fund Ltd (40) |
71,429 | 71,429 | — | — | — | — | — | — | ||||||||||||||||||||||||
Marathon Asset Management, L.P. (41) |
142,857 | 142,857 | — | — | — | — | — | — | ||||||||||||||||||||||||
Maven Investment Partners US Limited—New York Branch (42) |
107,143 | 107,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
BEMAP Master Fund Ltd. (43) |
121,870 | 91,260 | 30,610 | * | 18,969 | — | 18,969 | * | ||||||||||||||||||||||||
Bespoke Alpha MAC MIM LP (43) |
17,062 | 13,385 | 3,677 | * | 2,279 | — | 2,279 | * | ||||||||||||||||||||||||
DS Liquid Div RVA MON LLC (43) |
133,828 | 108,987 | 24,841 | * | 15,394 | — | 15,394 | * | ||||||||||||||||||||||||
Monashee Pure Alpha SPV I LP (43) |
73,887 | 56,760 | 17,127 | * | 10,613 | — | 10,613 | * | ||||||||||||||||||||||||
Monashee Solitario Fund LP (43) |
89,700 | 70,928 | 18,772 | * | 11,633 | — | 11,633 | * | ||||||||||||||||||||||||
SFL SPV I LLC (43) |
20,796 | 15,823 | 4,973 | * | 3,082 | — | 3,082 | * | ||||||||||||||||||||||||
North Lion Fund LLC (44) |
53,571 | 53,571 | — | — | — | — | — | — |
Shares of Common Stock |
Warrants to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
||||||||||||||||||||||||
Hartford Growth Fund Limited (45) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
One Fin Capital Master Fund LP (46) |
250,000 | 250,000 | — | — | 500,000 | — | 500,000 | * | ||||||||||||||||||||||||
Park West Partners International, Limited (47) |
1,123,976 | 191,147 | 932,829 | * | 193,963 | — | 193,963 | * | ||||||||||||||||||||||||
Park West Investors Master Fund, Limited (47) |
11,348,649 | 1,951,710 | 9,396,939 | 6.5 | % | 1,956,037 | — | 1,956,037 | 1.3 | % | ||||||||||||||||||||||
P.A.W. Small Cap Partners, LP (48) |
231,678 | 17,857 | 213,821 | * | — | — | — | — | ||||||||||||||||||||||||
Peridian Fund, L.P. (49) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
Senvest Master Fund, LP (50) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
Senvest Technology Partners Master Fund, LP (50) |
357,143 | 357,143 | — | — | — | — | — | — | ||||||||||||||||||||||||
Telemark Fund, LP (51) |
1,114,286 | 214,286 | 900,000 | * | 450,000 | — | 450,000 | * | ||||||||||||||||||||||||
Tenzing Global Investors Fund I, L.P. (52) |
432,810 | 158,764 | 274,046 | * | 137,023 | — | 137,023 | * | ||||||||||||||||||||||||
Pleiades Investment Partners—TE, L.P. (53) |
146,476 | 55,522 | 90,954 | * | 45,477 | — | 45,477 | * | ||||||||||||||||||||||||
Funds advised by Weiss Asset Management LP (54) |
357,143 | 357,143 | — | — | — | — | — | — |
* | Less than one percent |
(1) | Consists of 1,376,031 shares of Common Stock. Harrold Rust and Margaret Rust serve as trustees of the Harrold and Margaret Rust Family Trust UTD May 15, 1996 (the “Rust Family Trust”) and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by the Rust Family Trust. Mr. Rust is our President and Chief Executive Officer and a member of our board of directors since the Business Combination and has previously served as Legacy Enovix’s Chairperson, President and Chief Executive Officer since November 2006 when he founded Legacy Enovix. |
(2) | Consists of 334,428 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021. Mr. Rust is our President and Chief Executive Officer and a member of our board of directors since the Business Combination and has previously served as Legacy Enovix’s Chairperson, President and Chief Executive Officer since November 2006 when he founded Legacy Enovix. |
(3) | Consists of (i) 20,926,552 shares of Common Stock, including 3,800,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor, and (ii) 4,100,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Thurman J. Rodgers and Valeta Massey serve as trustees of the Rodgers Massey Revocable Living Trust dtd 4/4/11 (the “Rodgers Massey Trust”) and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by the Rodgers Massey Trust. Mr. Rodgers has served as a member of Legacy Enovix’s board of directors since February 2012 and serves as Chairman of our board of directors following the Business Combination. |
(4) | Consists of (i) 115,000 shares of Common Stock, after giving effect to an in-kind distribution of 5,635,000 shares of Common Stock to certain of the Sponsor’s members, and (ii) no shares of Common Stock issuable upon exercise of Private Placement Warrants, after giving effect to an in-kind distribution of 6,000,000 Private Placement Warrants to certain of the Sponsor’s members. Thurman J. Rodgers is the managing member of the Sponsor and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by the Sponsor. Mr. Rodgers has served as a member of Legacy Enovix’s board of directors since February 2012 and serves as Chairman of our board of directors following the Business Combination. |
(5) | Consists of (i) 185,768 shares of Common Stock, including 75,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor, (ii) 16,155 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021 and (iii) 100,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Betsy Atkins has served as a member of Legacy Enovix’s board of directors since January 2021 and continues to serve as a member of our board of directors after the Business Combination. |
(6) | Consists of (i) 460,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 500,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Emmanuel T. Hernandez served as the Chief Financial Officer and a director of RSVAC since November 2020 and is a member of our board of directors following the Business Combination. |
(7) | Consists of (i) 450,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 500,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. John D. McCranie served as a director of RSVAC since December 2020 and is a member of our board of directors following the Business Combination. |
(8) | Consists of 2,958,219 shares of Common Stock held by Michael John Petrick and Leslie Anderson Petrick, as Trustees of the Michael John Petrick Revocable Trust, as amended (the “Petrick Trust”). Michael J. Petrick holds voting and investment power over the shares held by the Petrick Trust. |
(9) | Consists of 90,004 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021. Michael J. Petrick has served as a member of Legacy Enovix’s board of directors since July 2018 and continues to serve as a member of our board of directors after the Business Combination. |
(10) | Consists of 15,629 shares of Common Stock. Gregory Reichow has served as a member of Legacy Enovix’s board of directors since November 2020 and continues to serve as a member of our board of directors after the Business Combination. |
(11) | Consists of (i) 988,603 shares of Common Stock and (ii) 27,616 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021. Cameron Dales has served as Legacy Enovix’s Chief Commercial Officer since September 2018 and continues to serve as our Chief Commercial Officer after the Business Combination. |
(12) | Consists of (i) 1,351,031 shares of Common Stock and (ii) 39,209 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021. Ashok Lahiri has served as Legacy Enovix’s Chief Technology Officer since June 2007 and continues to serve as our Chief Technology Officer after the Business Combination. |
(13) | Consists of (i) 2,000 shares of Common Stock (ii) 193,499 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021 and (iii) 1,000 shares of Common Stock issuable upon exercise of Public Warrants. Steffen Pietzke has served as Legacy Enovix’s Chief Financial Officer since April 2021 and continues to serve as our Chief Financial Officer after the Business Combination. |
(14) | Consists of (i) 156,921 shares of Common Stock and (ii) 35,858 shares of Common Stock issuable upon the exercise of stock options, which are exercisable within one year of July 19, 2021. Edward J. Hejlek has served as Legacy Enovix’s Vice President, General Counsel since January 2021 and continues to serve as our General Counsel after the Business Combination. From November 2020 to January 2021, Mr. Hejlek served as Legacy Enovix’s Vice President, Intellectual Property. |
(15) | Consists of (i) 295,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 300,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Steven J. Gomo served as a director of RSVAC from December 2020 to the Closing Date. |
(16) | Consists of (i) 262,500 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 250,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Lisan Hung served as a director of RSVAC from December 2020 to the Closing Date. |
(17) | Consists of (i) 262,500 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 250,000 shares of Common Stock issuable upon exercise of Private Placement Warrants acquired via an in-kind distribution from the Sponsor. Joseph I. Malchow served as a director of RSVAC from December 2020 to the Closing Date. |
(18) | Consists of (i) 40,000 shares of Common stock, including 10,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor and (ii) 15,000 shares of Common Stock issuable upon exercise of Public Warrants. |
(19) | Consists of 10,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor. |
(20) | Consists of 10,000 shares of Common Stock acquired via an in-kind distribution from the Sponsor. Ralph Schmitt served as a member of RSVAC’s Technical Advisory Board from October 2020 to January 2021. Mr. Schmitt also served as Legacy Enovix’s Vice President of Sales and Business Development since January 2021 and continues to serve as our Vice President of Sales and Business Development after the Business Combination. |
(21) | Consists of 17,583,258 shares of Common Stock held by Eclipse Fund III, L.P., or Eclipse III. Eclipse GP III, LLC, or Eclipse III GP, is the general partner of Eclipse III and may be deemed to have voting and dispositive power over the shares held by Eclipse III. Lior Susan is the sole managing member of Eclipse III GP and may be deemed to have voting and dispositive power over the shares held by Eclipse III. Eclipse III GP and Mr. Susan disclaim beneficial ownership of the shares held by Eclipse III except to the extent of their pecuniary interest therein, if any. The address for Eclipse Fund III is 514 High Street, Suite 4, Palo Alto, CA 94301. |
(22) | Ardsley Partners Renewable Energy Fund, L.P. is managed by Ardsley Advisory Partners LP. Spencer Hempleman and Philip J. Hempleman have voting and investment control of the shares held by Ardsley Partners Renewable Energy Fund, L.P. and, accordingly, may be deemed to have beneficial ownership of such shares. The address of Ardsley Partners Renewable Energy Fund, L.P. is 262 Harbor Drive, 4th Floor, Stamford, CT 06902. |
(23) | Atlas Diversified Master Fund, Ltd. is managed by Balyasny Asset Management, L.P. Linburgh Martin, John Sutlic and Scott Schroeder, as directors of Balyasny Asset Management, L.P., have voting and investment control of the shares held by Atlas Diversified Master Fund, Ltd. and, accordingly, may be deemed to have beneficial ownership of such shares. The address of Atlas Diversified Master Fund, Ltd. is P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. |
(24) | Crossroads Investments, LP (“Crossroads Investments”) is the investment manager for Crossroads Partners, LP (“Crossroads Partners”). Alexander Greenberg is the managing partner of Crossroads Advisors, LLC, Crossroads Partner’s general partner, and the principal of Crossroads Investments and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by Crossroads Investments. The address of the foregoing entities is 595 Madison Avenue, 8th Floor, New York, NY 10022. |
(25) | As of July 14, 2021, D. E. Shaw Oculus Portfolios, L.L.C. holds 89,286 shares of common stock of the Company to be registered for resale pursuant to the registration statement (the “Oculus Subject Shares”). D. E. Shaw Oculus Portfolios, L.L.C. has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) the Oculus Subject Shares directly owned by it. |
(26) | As of July 14, 2021, D. E. Shaw Valence Portfolios, L.L.C. holds (i) 267,857 shares of common stock of the Company to be registered for resale pursuant to the registration statement and (ii) 145,901 shares of the Company’s common stock issuable upon the exercise of warrants at an exercise price of $11.50 per share to be registered for resale pursuant to the registration statement (collectively, the “Valence Subject Shares”). D. E. Shaw Valence Portfolios, L.L.C. has the power to vote or to direct the vote of (and the power to dispose or direct the disposition of) the Valence Subject Shares directly owned by it. |
(27) | DG Capital Management, LLC (“DG Capital”) is the investment manager for DG Value Partners, LP, DG Value Partners II Master Fund, LP and DG Value Partners II Master Fund, LP—Class C. Mr. Dov Gertzulin is the managing member of DG Capital and has voting and investment power over the shares held by the foregoing entities. The address for DG Capital and the foregoing entities is 460 Park Ave. 22nd Floor, New York, New York 10022. |
(28) | Electron Capital Partners, LLC is the investment manager for Electron Global Master Fund L.P. and Electron Infrastructure Master Fund, L.P, and it is the sub-investment manager for AGR Trading SPC-Series EC Segregated Portfolio and Boothbay Absolute Return Strategies, LP (collectively, the “Electron Securityholders”). James Shaver may be deemed to have investment discretion and voting power over the shares held by the Electron Securityholders. The address of each entity listed in this footnote is 10 East 53rd Street, 19th Floor, New York, NY 10022. |
(29) | Voting and investment power of the shares held by PMT Capital, L.P. resides with Patrick M. Tenney, as Trustee of The Patrick M. Tenney Revocable Trust, dated July 31, 2007, its general partner. The address of PMT Capital, L.P. and its general partner is 591 Redwood Highway, Suite 2100, Mill Valley, CA 94941. |
(30) | Fir Tree Capital Management, LP (“FTCM”) is the investment manager for the Fir Tree funds. David Sultan and Clinton Biondo control FTCM. Each of FTCM, Messrs. Sultan and Biondo has voting and investment power with respect to the shares owned by the Fir Tree funds and may deemed to be the beneficial owner of such shares. The address of FTCM is 55 West 46th Street, New York, NY 10036. |
(31) | John M. Stein holds voting and investment power over the shares held by John M. Stein Roth IRA. |
(32) | Voting and investment power over the shares held by Fort Baker Catalyst Master Fund, LP resides with its investment manager, Fort Baker Capital Management LP. The address of Fort Baker Catalyst Master Fund, LP is c/o Maples Corporate Services, P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. |
(33) | Consists of (i) 180,980 shares held by Glazer Enhanced Fund, L.P., (ii) 458,013 shares held by Glazer Enhanced Offshore Fund, Ltd., and (iii) 75,293 shares held by Highmark Limited, In Respect of its Segregated Account, Highmark Multi-Strategy 2 (collectively, the “Glazer Funds”). Voting and investment power over the shares held by such entities resides with their investment manager, Glazer Capital, LLC (“Glazer Capital”). Mr. Paul J. Glazer (“Mr. Glazer”) serves as the Managing Member of Glazer Capital and may be deemed to be the beneficial owner of the shares held by such entities. Mr. Glazer, however, disclaims any beneficial ownership of the shares held by such entities. The address of the foregoing individuals and entities is c/o Glazer Capital, LLC, 250 West 55th Street, Suite 30A, New York, New York 10019. |
(34) | Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc. (“CVI”), has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI. Mr. Kobinger disclaims any such beneficial ownership of the shares. The address of CVI is c/o Heights Capital Management, Inc., 101 California Street, Suite 3250, San Francisco, California 94111. |
(35) | Hudson Bay Capital Management LP, the investment manager of Tech Opportunities LLC, has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Tech Opportunities LLC and Sander Gerber disclaims beneficial ownership over these securities. |
(36) | Kepos Capital LP is the investment manager of the Selling Securityholder and Kepos Partners LLC is the General Partner of the Selling Securityholder and each may be deemed to have voting and dispositive power with respect to the shares. The general partner of Kepos Capital LP is Kepos Capital GP LLC (the “Kepos GP”) and the Managing Member of Kepos Partners LLC is Kepos Partners MM LLC (“Kepos MM”). Mark Carhart controls Kepos |
GP and Kepos MM and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by this Selling Securityholder. Mr. Carhart disclaims beneficial ownership of the shares held by the Selling Securityholder. |
(37) | Jon D. Gruber is the trustee of the Jon D and Linda W Gruber Trust. Mr. Gruber may therefore be deemed to be a beneficial owner of the shares held by the Jon D and Linda W Gruber Trust. |
(38) | LMR Partners LLP (“LMR Partners”) is the investment manager of LMR CCSA Master Fund Limited and LMR Master Fund Limited (together, the “LMR Securityholders”). Vincent Olekhnovitch is a portfolio manager of LMR Partners, and Pearse Griffith, Benjamin Levine, Torsten de Santos and Mark Eberle are directors of the LMR Securityholders, and, accordingly, they have shared voting and dispositive power of the shares held by the LMR Securityholders. The address of LMR Partners is 9th Floor, Devonshire House, 1 Mayfair Place, London W1J 8AJ. The address of the LMR Securityholders is P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104 Cayman Islands. |
(39) | The Selling Securityholder is managed by Luminus Management LLC. Jonathan Barrett has voting and investment power over the shares held by the Selling Securityholder. The address of the Selling Securityholder is 1700 Broadway, 16th Floor, New York, NY 10019. |
(40) | The registered holders of the shares are the following funds and accounts that are managed by Magnetar Financial LLC (“MFL”), which serves as investment manager of each Magnetar Capital Master Fund, Ltd, Magnetar Discovery Master Fund Ltd, Purpose Alternative Credit Fund Ltd, Purpose Alternative Credit Fund—T LLC, Magnetar Constellation Master Fund, Ltd., Magnetar Constellation Fund II, Ltd, Magnetar Longhorn Fund LP, Magnetar SC Fund Ltd, and Magnetar Xing He Master Fund Ltd. MFL is the manager of Magnetar Lake Credit Fund LLC. MFL is the general partner of Magnetar Structured Credit Fund, LP (together with all of the foregoing funds, the “Magnetar Funds”). In such capacities, MFL exercises voting and investment power over the securities listed above held for the accounts of the Magnetar Funds. MFL is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended. Magnetar Capital Partners LP (“MCP”), is the sole member and parent holding company of MFL. Supernova Management LLC (“Supernova”), is the sole general partner of MCP. The manager of Supernova is Alec N. Litowitz, a citizen of the United States of America. Each of the Magnetar Funds, MFL, MCP, Supernova and Alec N. Litowitz disclaim beneficial ownership of these securities except to the extent of their pecuniary interest in the securities. Shares shown include only the securities being registered for resale and may not incorporate all interests deemed to be beneficially held by the registered holders described above or by other investment funds managed or advised by MFL. |
(41) | Marathon Asset Management GP, L.L.C. (“Marathon GP”) is the general partner of Marathon Asset Management, L.P. (“Marathon Asset Management”). Bruce Richards and Louis Hanover are managing members of Marathon GP and the Chief Executive Officer and Chief Investment Officer, respectively, of Marathon Asset Management and, accordingly, have voting and dispositive power over the shares held by Marathon Asset Management. Mr. Richards and Mr. Hanover, however, each disclaim any beneficial ownership of the shares held by Marathon Asset Management. The address of the foregoing individuals and Marathon Asset Management is c/o Marathon Asset Management, L.P., One Bryant Park, 38th Floor, New York, NY 10036. |
(42) | Anand K. Sharma may be deemed to have investment discretion and voting power over the securities held by the Selling Securityholder. The address of Maven Investment Partners US Limited—New York Branch is 675 3rd Avenue, 15th Floor, New York, NY 10017. |
(43) | Each of DS Liquid Div RVA MON LLC (“DS”), BEMAP Master Fund Ltd. (“BEMAP”), Monashee Solitario Fund LP (“Solitario”), Monashee Pure Alpha SPV I LP (“Pure Alpha”), SFL SPV I LLC (“SFL”) and Bespoke Alpha MAC MIM LP (“Bespoke”) is managed by Monashee Investment Management, LLC (“Monashee Management”). Jeff Muller is CCO of Monashee Management and has voting and investment control over Monashee Management and, accordingly, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL, and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee Management and Mr. Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. |
(44) | Voting and investment power over the shares held by North Lion Fund LLC resides with North Lion Capital Management LLC (“NLCM”), its managing member. Chad A. Anderson is the managing partner of NLCM. The address of each entity and Mr. Anderson is 60 South 6th Street, Suite 2560, Minneapolis, MN 55402. |
(45) | Voting and investment power over the shares held by Hartford Growth Fund Limited resides with Omni Partners LLP. The address of Hartford Growth Fund Limited is c/o Omni Partners LLP, 4th Floor, 15 Golden Square, London, W1F 9JG, United Kingdom. |
(46) | Voting and investment power over the shares held by One Fin Capital Master Fund LP resides with One Fin Capital Management LP, its Investment Advisor. David MacKnight is the principal of One Fin Capital Management LP. The address of each entity is One Letterman Drive, Building C, Suite C3-400, San Francisco, CA 94129. |
(47) | Park West Asset Management LLC is the investment manager to Park West Investors Master Fund, Limited and Park West Partners International, Limited, and Peter S. Park, through one or more affiliated entities, is the controlling manager of Park West Asset Management LLC. |
(48) | Voting and investment power over the shares held by P.A.W Small Cap Partners, L.P. resides with P.A.W. Capital Partners, L.P. (“P.A.W. Partners”), its general partner. Peter A. Wright is the Chief Investment Officer, General Partner and Senior Portfolio Manager of P.A.W. Partners. The address of P.A.W. Small Cap Partners, L.P. is c/o P.A.W. Capital Partners, L.P., 4 Greenwich Office Park, 3rd Floor, Greenwich, CT 06831. |
(49) | Shares offered hereby consist of 357,143 shares held by Peridian Fund, L.P (“Peridian”). Voting and investment power over the shares held by Peridian resides with its investment manager, Periscope Capital Inc. Jamie Wise is the Chief Executive Officer of Periscope Capital Inc. and may be deemed to be the beneficial owner of the shares held by Peridian. Jamie Wise and Periscope Capital Inc., however, disclaim any beneficial ownership of the shares held by Peridian. The address of the foregoing individual and entities is c/o 333 Bay Street, Suite 1240, Toronto, ON, M5H 2R2. |
(50) | Senvest Management, LLC may be deemed to beneficially own the securities held by Senvest Master Fund, LP and Senvest Technology Partners Master Fund, LP (the “Senvest Investment Vehicles”) by virtue of Senvest Management, LLC’s position as investment manager of the Senvest Investment Vehicles. Richard Mashaal may be deemed to beneficially own the securities held by the Senvest Investment Vehicles by virtue of Mr. Mashaal’s status as the managing member of Senvest Management, LLC. The mailing address of the foregoing entities is 540 Madison Avenue 32nd Floor, New York, NY 10022. |
(51) | Telemark Asset Management, LLC (“Telemark Asset Management”) is the investment adviser of Telemark Fund, LP (“Telemark Fund”). Colin McNay is the President and sole owner of Telemark Asset Management and has voting and investment control over Telemark Asset Management and, |
accordingly, may be deemed to have beneficial ownership of such shares held by Telemark Fund. The address of the foregoing entities is One International Place, Suite 4620 Boston MA, 02110. |
(52) | Tenzing Global Investors LLC (“Tenzing Global Investors”) is the general partner of Tenzing Global Investors Fund I LP (“Tenzing Fund I”). Chet Kapoor is a managing member of Tenzing Global Investors and portfolio manager of Tenzing Fund I and has voting and investment control over the shares held by Tenzing Fund I. The principal address of the foregoing entities is 90 New Montgomery, Suite 650, San Francisco, CA 94105. |
(53) | Tenzing Global Investors is the investment manager of Pleiades Investment Partners—TE, L.P. (“Pleiades”). Chet Kapoor is a managing member of Tenzing Global Investors and portfolio manager of Pleiades and has voting and investment control over the shares held by Pleiades. The principal address of Tenzing Global Investors is 90 New Montgomery, Suite 650, San Francisco, CA 94105, and the principal address of Pleiades is 6022 West Chester Pike, Newton Square, PA 19073. |
(54) | Consists of (i) 132,143 shares held by Brookdale Global Opportunity Fund (“BGO”) and (ii) 225,000 shares held by Brookdale International Partners, L.P. (“BIP”). Andrew Weiss is the Manager of WAM GP LLC, which is the general partner of Weiss Asset Management LP, the investment manager of BGO and BIP. WAM GP LLC is also the Manager of BIP GP LLC, the general partner of BIP. Mr. Weiss has voting and dispositive power with respect to the securities held by BGO and BIP. Mr. Weiss, WAM GP LLC, Weiss Asset Management LP and BIP GP LLC each disclaim beneficial ownership of the shares held by BGO and BIP, except to the extent of their respective pecuniary interests therein. The business address of the foregoing entities is c/o Weiss Asset Management, 222 Berkeley Street, 16th Floor, Boston, MA 02116. |
• | at any time while the Private Placement Warrants are exercisable, |
• | upon not less than 30 days’ prior written notice of redemption to each warrant holder, |
• | if, and only if, the reported last sale price of the shares of Common Stock equals or exceeds $18.00 per share, for any 20 trading days within a 30-day trading period ending on the third business day prior to the notice of redemption to warrant holders, and |
• | if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such Private Placement Warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. |
• | permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that the authorized number of directors may be changed only by resolution of our board of directors; |
• | provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least 66 2 /3 % of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors; |
• | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that Special Meetings of our stockholders may be called by the chairperson of our board of directors, the chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | prior to the date of the transaction, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
• | the interested stockholder owned at least 85% of our voting stock outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
• | on or subsequent to the consummation of the transaction, the business combination is approved by our board of directors and authorized at an annual or Special Meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2 /3 % of the outstanding voting stock which is not owned by the interested stockholder. |
• | 1% of the total number of shares of our Common Stock then outstanding; or |
• | the average weekly reported trading volume of our Common Stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
• | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
• | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
• | at least one year has elapsed from the time that the issuer filed current Form 10-type information with the SEC reflecting its status as an entity that is not a shell company. |
• | any breach of the director’s duty of loyalty to us or to our stockholders; |
• | acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |
• | unlawful payment of dividends or unlawful stock repurchases or redemptions; and |
• | any transaction from which the director derived an improper personal benefit. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
• | a trust if (a) a U.S. court can exercise primary supervision over the trust’s administration and one or more U.S. persons have the authority to control all of the trust’s substantial decisions or (b) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. |
• | the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder); |
• | the non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or |
• | we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our Common Stock or Warrants and, in the case where shares of our Common Stock are regularly traded on an established securities market, the non-U.S. Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our Common Stock. These rules may be modified as applied to the Warrants. There can be no assurance that our Common Stock will be treated as regularly traded or not regularly traded on an established securities market for this purpose. |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter |
• | through trading plans entered into by a Selling Securityholder pursuant to Rule 10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | short sales; |
• | distribution to employees, members, limited partners or stockholders of the Selling Securityholders; |
• | through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | to or through underwriters or broker-dealers; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | in privately negotiated transactions; |
• | in options transactions; or |
• | any other method permitted pursuant to applicable law. |
Unaudited Condensed Consolidated Financial Statements |
||||
F-2 |
||||
F-3 |
||||
F-4 |
||||
F-5 |
||||
F-6 |
||||
Audited Consolidated Financial Statements |
||||
F-17 |
||||
F-18 |
||||
F-19 |
||||
F-20 |
||||
F-21 |
||||
F-23 |
April 3, 2022 |
January 2, 2022 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Deferred contract costs |
||||||||
Prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
Property and equipment, net |
||||||||
Operating lease, right-of-use |
||||||||
Other assets, non-current |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
Liabilities and Stockholders’ Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Accrued compensation |
||||||||
Deferred revenue |
||||||||
Other liabilities |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
Warrant liability |
||||||||
Operating lease liabilities, non-current |
||||||||
Deferred revenue, non-current |
||||||||
Other liabilities, non-current |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
Commitments and Contingencies (Note 6) |
||||||||
Stockholders’ equity: |
||||||||
Common stock, $ |
||||||||
Preferred stock, $ |
||||||||
Additional paid-in-capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
Total liabilities and stockholders’ equity |
$ | $ | ||||||
|
|
|
|
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Operating expenses: |
||||||||
Cost of revenue |
$ | $ | ||||||
Research and development |
||||||||
Selling, general and administrative |
||||||||
Total operating expenses |
||||||||
Loss from operations |
( |
) | ( |
) | ||||
Other income (expense): |
||||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
( |
) | ||||||
Other income (expense), net |
( |
) | ||||||
Total other income (expense), net |
( |
) | ||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Net income (loss) per share, basic |
$ | $ | ( |
) | ||||
Weighted average number of common shares outstanding, basic |
||||||||
Net loss per share, diluted |
$ | ( |
) | $ | ( |
) | ||
Weighted average number of common shares outstanding, diluted |
Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance as of January 2, 2022 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | ||||||||||||||||||
Issuance of common stock upon exercise of common stock warrants |
— | — | ||||||||||||||||||
Vesting of early exercised stock options |
— | — | — | |||||||||||||||||
Vesting of restricted stock units |
— | — | — | — | ||||||||||||||||
Repurchase of unvested restricted common stock |
( |
) | — | — | — | — | ||||||||||||||
Stock-based compensation |
— | — | — | |||||||||||||||||
Net income |
— | — | — | |||||||||||||||||
Balance as of April 3, 2022 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholders’ Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance as of December 31, 2020, effect of reverse acquisition |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | ||||||||||||||||||
Vesting of early exercised stock options |
— | — | — | |||||||||||||||||
Repurchase of unvested restricted common stock |
( |
) | — | — | — | — | ||||||||||||||
Issuance of Series D convertible preferred stock upon exercise of warrants |
— | — | ||||||||||||||||||
Stock-based compensation |
— | — | — | |||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
Balance as of March 31, 2021 |
$ |
$ |
$ |
( |
) |
$ |
||||||||||||||
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
$ | $ | ( |
) | ||||
Adjustments to reconcile net income (loss) to net cash used in operating activities |
||||||||
Depreciation |
||||||||
Amortization of right-of-use |
||||||||
Stock-based compensation expense |
||||||||
Changes in fair value of convertible preferred stock warrants and common stock warrants |
( |
) | ||||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses and other assets |
( |
) | ||||||
Deferred contract costs |
( |
) | ||||||
Accounts payable |
( |
) | ||||||
Accrued expenses and compensation |
||||||||
Other liabilities |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash flows from investing activities: |
||||||||
Purchase of property and equipment |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash flows from financing activities: |
||||||||
Payments of transaction costs related to Business Combination and PIPE financing |
( |
) | ||||||
Proceeds from exercise of common stock warrants, net |
||||||||
Proceeds from exercise of convertible preferred stock warrants |
||||||||
Proceeds from the exercise of stock options |
||||||||
Repurchase of unvested restricted common stock |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net cash provided by (used in) financing activities |
( |
) | ||||||
|
|
|
|
|||||
Change in cash, cash equivalents, and restricted cash |
( |
) | ||||||
Cash and cash equivalents and restricted cash, beginning of period |
||||||||
|
|
|
|
|||||
Cash and cash equivalents and restricted cash, end of period |
$ | $ | ||||||
|
|
|
|
|||||
Supplemental cash flow data (Non-cash): |
||||||||
Purchase of property and equipment included in liabilities |
$ | $ | ||||||
Accrued transaction costs |
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Cash and cash equivalents |
$ | $ | ||||||
Restricted cash included in prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total cash, cash equivalents, and restricted cash |
$ | $ | ||||||
|
|
|
|
Level 1: | Observable inputs, such as quoted prices (unadjusted) in active markets for identical assets or liabilities at the measurement date. | |
Level 2: | Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | |
Level 3: | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
Fair Value Measurement using |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total Fair Value |
|||||||||||||
As of April 3, 2022 |
||||||||||||||||
Liabilities: |
||||||||||||||||
Private Placement Warrants |
$ | |
$ | |
$ | $ | ||||||||||
As of January 2, 2022 |
||||||||||||||||
Liabilities: |
||||||||||||||||
Private Placement Warrants |
$ | $ | $ | $ |
Private Placement Warrants |
||||
Fair value as of January 2, 2022 |
$ | |||
Change in fair value |
( |
) | ||
Fair value as of April 3, 2022 |
$ | |||
Convertible Preferred Stock Warrants |
||||
Fair value as of December 31, 2020 |
$ | |||
Settlements |
( |
) | ||
Change in fair value |
||||
Fair value as of March 31, 2021 |
$ | |||
Private Placement Warrants outstanding as of April 3, 2022 |
Private Placement Warrants outstanding as of January 2, 2022 |
Convertible preferred stock warrants exercised on February 22, 2021 | ||||
Expected term (in years) |
||||||
Expected volatility |
||||||
Risk-free interest rate |
||||||
Expected dividend rate |
April 3, 2022 |
January 2, 2022 |
|||||||
Process equipment |
$ | $ | ||||||
Office equipment |
||||||||
Furniture and fixtures |
||||||||
Leasehold improvements |
||||||||
Construction in progress |
||||||||
Total property and equipment |
||||||||
Less: Accumulated depreciation |
( |
) | ( |
) | ||||
Property and equipment, net |
$ | $ | ||||||
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Operating lease cost |
$ | $ |
As of |
||||||||
Operating leases |
April 3, 2022 |
March 31, 2021 |
||||||
Weighted-average remaining lease term |
||||||||
Weighted-average discount rate |
% | % |
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Cash paid for amounts included in the measurement of lease liabilities: |
||||||||
Operating cash flows from operating leases |
$ | $ | ||||||
Lease liabilities arising from obtaining ROU assets: |
||||||||
Operating leases |
— |
Operating lease |
||||
2022 (remaining nine months) |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
Total |
||||
Less: imputed interest |
( |
) | ||
Present value of lease liabilities |
$ | |||
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Numerator: |
||||||||
Net income (loss) attributable to common stockholders — basic |
$ | $ | ( |
) | ||||
Increase in fair value of Private Placement Warrants |
( |
) | ||||||
Net loss attributable to common stockholders — Diluted |
$ | ( |
) | $ | ( |
) | ||
Denominator: |
||||||||
Weighted-average shares outstanding used in computing net income (loss) per share of common stock, basic |
||||||||
Dilutive effect of Private Placement Warrants |
||||||||
Weighted-average shares outstanding used in computing net loss per share of common stock, diluted |
||||||||
Net income (loss) per share of common stock: |
||||||||
Basic |
$ | $ | ( |
) | ||||
Diluted |
$ | ( |
) | $ | ( |
) |
April 3, 2022 |
March 31, 2021 |
|||||||
Stock options outstanding |
||||||||
Restricted stock units outstanding |
||||||||
Employee stock purchase plan estimated shares |
For the Quarters Ended |
||||||||
April 3, 2022 |
March 31, 2021 |
|||||||
Cost of revenue |
$ | $ | ||||||
Research and development |
||||||||
Selling, general and administrative |
||||||||
Total stock-based compensation expense |
$ | $ | ||||||
Number of Options Outstanding |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life (Years) |
Aggregate Intrinsic Value (1)(2) |
|||||||||||||
Balances as of January 3, 2022 |
$ | |||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | $ | |||||||||||||
Forfeited |
( |
) | ||||||||||||||
Balances as of April 3, 2022 |
$ | $ | ||||||||||||||
Vested and expected to vest at April 3, 2022 |
$ | $ | ||||||||||||||
Vested and exercisable at April 3, 2022 |
$ | $ | ||||||||||||||
Unvested and exercisable at April 3, 2022 |
$ | $ | ||||||||||||||
(1) |
The intrinsic value of options exercised is based upon the value of the Company’s stock at exercise. |
(2) |
The aggregate intrinsic value of the stock options outstanding as of April 3, 2022 represents the value of the Company’s closing stock price at $ on April 1, 2022 in excess of the exercise price multiplied by the number of options outstanding. |
Number of Shares Outstanding |
Weighted Average Grant Date Fair Value |
|||||||
Non-vested RSUs Balances as of January 2, 2022 |
$ | |||||||
Granted |
||||||||
Vested |
( |
) | ||||||
Forfeited |
( |
) | ||||||
Non-vested RSUs outstanding as of April 3, 2022 |
$ | |||||||
January 2, 2022 |
December 31, 2020 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Deferred contract costs |
||||||||
Prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
Property and equipment, net |
||||||||
Operating lease, right-of-use |
— | |||||||
Deferred contract costs, non-current |
— | |||||||
Other assets, non-current |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
Liabilities, Convertible Preferred Stock and Stockholders’ Equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Accrued compensation |
||||||||
Deferred revenue |
||||||||
Other liabilities |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
Deferred rent, non-current |
— | |||||||
Warrant liability |
||||||||
Operating lease liabilities, non-current |
— | |||||||
Deferred revenue, non-current |
||||||||
Other liabilities, non-current |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
Commitments and Contingencies (Note 8) |
||||||||
Stockholders’ equity: |
||||||||
Common stock, $ |
||||||||
Preferred stock, $ |
||||||||
Additional paid-in-capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
Total liabilities, convertible preferred stock and stockholders’ equity |
$ | $ | ||||||
|
|
|
|
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Operating expenses: |
||||||||
Cost of revenue |
$ | $ | ||||||
Research and development |
||||||||
Selling, general and administrative |
||||||||
|
|
|
|
|||||
Total operating expenses |
||||||||
|
|
|
|
|||||
Loss from operations |
( |
) | ( |
) | ||||
Other income (expense): |
||||||||
Change in fair value of convertible preferred stock warrants and common stock warrants |
( |
) | ( |
) | ||||
Issuance of convertible preferred stock warrants |
( |
) | ||||||
Change in fair value of convertible promissory notes |
( |
) | ||||||
Gain on extinguishment of paycheck protection program loan |
||||||||
Interest expense, net |
( |
) | ( |
) | ||||
Other income (expense), net |
( |
) | ||||||
|
|
|
|
|||||
Total other expense, net |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Net loss per share, basic and diluted |
$ | ( |
) | $ | ( |
) | ||
Weighted average number of common shares outstanding, basic and diluted |
Convertible Preferred Stock |
Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholders’ Equity (Deficit) |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
Balance as of December 31, 2019 (as previously reported) |
$ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||
Retroactive application of recapitalization |
( |
) | ( |
) | ( |
) | ( |
) | — | |||||||||||||||||||
Balance as of December 31, 2019, effect of reverse acquisition (Note 3) |
— |
— |
( |
) |
||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | — | |||||||||||||||||||||||||
Vesting of early exercised stock options |
— | — | — | — | — | |||||||||||||||||||||||
Issuance of Series P-2 convertible preferred stock |
— | — | — | |||||||||||||||||||||||||
Conversion of promissory notes to Series P-2 convertible preferred stock |
— | — | — | — | ||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | |||||||||||||||||||||||
Repurchase of unvested restricted common stock |
— | — | ( |
) | — | — | — | — | ||||||||||||||||||||
Balance as of December 31, 2020 |
— |
— |
( |
) |
||||||||||||||||||||||||
Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
Business combination, net of redemptions and equity issuance costs and PIPE financing, net |
— | — | — | |||||||||||||||||||||||||
Issuance of common stock upon exercise of common stock warrants |
— | — | — | |||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | — | — | ||||||||||||||||||||||||
Issuance of Series D convertible preferred stock upon exercise of warrants |
— | — | — | — | ||||||||||||||||||||||||
Vesting of restricted stock units |
— | — | — | — | — | — | ||||||||||||||||||||||
Vesting of early exercised stock options |
— | — | — | — | — | |||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | |||||||||||||||||||||||
Repurchase of unvested restricted common stock |
— | — | ( |
) | — | — | — | — | ||||||||||||||||||||
Balance as of January 2, 2022 |
— |
$ |
— |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities |
||||||||
Depreciation |
||||||||
Amortization of right-of-use |
||||||||
Stock-based compensation expense |
||||||||
Changes in fair value of convertible preferred stock warrants and common stock warrants |
||||||||
Issuance of convertible preferred stock warrants (non-cash) |
||||||||
Change in fair value of convertible promissory notes |
||||||||
Loss (gain) on early debt extinguishment |
( |
) | ||||||
Interest expense (non-cash) |
||||||||
Changes in operating assets and liabilities: |
||||||||
Prepaid expenses and other assets |
( |
) | ( |
) | ||||
Deferred contract costs |
( |
) | ( |
) | ||||
Accounts payable |
||||||||
Accrued expenses and compensation |
||||||||
Deferred revenue |
||||||||
Deferred rent |
||||||||
Other liabilities |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash flows from investing activities: |
||||||||
Purchase of property and equipment |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Cash flows from financing activities: |
||||||||
Proceeds from Business Combination and PIPE financing |
||||||||
Payments of transaction costs related to Business Combination and PIPE financing |
( |
) | ||||||
Proceeds from issuance of convertible preferred stock, net |
||||||||
Proceeds from exercise of common stock warrants |
||||||||
Proceeds from secured promissory notes, converted promissory notes and paycheck protection program loan |
||||||||
Proceeds from paycheck protection program loan |
||||||||
Repayment of secured promissory note |
( |
) | ||||||
Payment of debt issuance costs |
( |
) | ||||||
Proceeds from exercise of convertible preferred stock warrants |
||||||||
Proceeds from the exercise of stock options |
||||||||
Repurchase of unvested restricted common stock |
( |
) | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
||||||||
|
|
|
|
|||||
Change in cash, cash equivalents, and restricted cash |
||||||||
Cash and cash equivalents and restricted cash, beginning of period |
||||||||
|
|
|
|
|||||
Cash and cash equivalents and restricted cash, end of period |
$ | $ | ||||||
|
|
|
|
|||||
Supplemental cash flow data (Non-cash): |
||||||||
Net liabilities assumed from Business Combination |
$ | $ | ||||||
Accrued purchase of property and equipment |
||||||||
Conversion of promissory notes to convertible preferred stock |
||||||||
Settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock |
||||||||
Issuance of convertible preferred stock warrants |
||||||||
Gain on extinguishment of the paycheck protection program loan |
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Cash and cash equivalents |
$ | $ | ||||||
Restricted cash included in prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total cash, cash equivalents, and restricted cash |
$ | $ | ||||||
|
|
|
|
Useful Life (Years) | ||
Process equipment |
||
Office equipment |
||
Furniture and fixtures |
||
Leasehold improvements |
Shorter of the economic life or the remaining lease term |
• | Level 1 — Observable inputs, such as quoted prices (unadjusted) in active markets for identical assets or liabilities at the measurement date; |
• | Level 2 — Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and |
• | Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
1. | Identify the contract with the customer |
2. | Identify the performance obligations in the contract |
3. | Determine the transaction price |
4. | Allocate the transaction price to the performance obligations in the contract |
5. | Recognize revenue when, or as, a performance obligation is satisfied |
• |
Expected Term — The expected term of the options represents the average period the share options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term of options granted is derived from the average midpoint between the weighted average vesting and the contractual |
term, also known as the simplified method. The Company uses the simplified calculation of the expected life, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option. |
• |
Risk-Free Interest Rate — The risk-free interest rate is based on the yield of U.S. Treasury notes as of the grant date with terms commensurate with the expected term of the option. |
• |
Dividend Yield — The expected dividends assumption is based on the Company’s expectation of not paying dividends in the foreseeable future, as well as the Company did not pay any dividends in the past. |
• |
Volatility — Prior to the Business Combination, Legacy Enovix was a private company and did not have any trading history for its ordinary shares, the expected volatility was based on the historical volatilities of the common stock of comparable publicly traded companies that Legacy Enovix selected with comparable characteristics, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the Legacy Enovix’s stock options. |
December 31, 2020 |
Adjustments from Adoption of ASC 842 |
January 1, 2021 |
||||||||||
Operating lease, right-of-use |
$ | $ | $ | |||||||||
Other liabilities |
( |
) | ||||||||||
Deferred rent, non-current |
( |
) | ||||||||||
Operating lease liabilities, non-current |
RSVAC common stock shares outstanding prior to the Business Combination |
||||
Less redemption of RSVAC common stock shares |
( |
) | ||
RSVAC common stock shares |
||||
PIPE Shares issued |
||||
RSVAC common stock shares and PIPE Shares |
||||
Legacy Enovix common shares (1) |
||||
Total shares of Common Stock immediately after the Business Combination |
||||
(1) |
The number of Legacy Enovix common shares was determined from the shares of Legacy Enovix common stock outstanding immediately prior to the closing of the Business Combination converted at the exchange ratio of approximately . All fractional shares were rounded. |
Recapitalization |
||||
Cash — RSVAC Trust and cash, net of redemptions |
$ | |||
Cash — PIPE Financing |
||||
Less: transaction costs and PIPE financing fees |
( |
) | ||
|
|
|||
Net cash contributions from Business Combination |
$ | |||
|
|
Level 1: | Observable inputs, such as quoted prices (unadjusted) in active markets for identical assets or liabilities at the measurement date. | |
Level 2: | Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | |
Level 3: | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
Fair Value Measurement using |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total Fair Value |
|||||||||||||
As of January 2, 2022 |
||||||||||||||||
Liabilities: |
||||||||||||||||
Private Placement Warrants |
$ | $ | $ | $ | ||||||||||||
As of December 31, 2020 |
||||||||||||||||
Liabilities: |
||||||||||||||||
Convertible preferred stock warrants |
$ | $ | $ | $ |
Private Placement Warrants |
Convertible Preferred Stock Warrants |
|||||||
Fair value as of December 31, 2020 |
$ | $ | ||||||
Acquired from the Business Combination |
||||||||
Settlements |
( |
) | ||||||
Change in fair value |
||||||||
|
|
|
|
|||||
Fair value as of January 2, 2022 |
$ | $ | ||||||
|
|
|
|
Convertible Promissory Notes |
Convertible Preferred Stock Warrants |
|||||||
Fair value as of December 31, 2019 |
$ | $ | ||||||
Additions |
||||||||
Settlements |
( |
) | ||||||
Change in fair value |
||||||||
|
|
|
|
|||||
Fair value as of December 31, 2020 |
$ | $ | ||||||
|
|
|
|
Private Placement Warrants outstanding as of January 2, 2022 |
Private Placement Warrants acquired on July 14, 2021 |
Convertible preferred stock warrants exercised on February 22, 2021 |
Convertible preferred stock warrants outstanding as of December 31, 2020 | |||||
Expected term (in years) |
||||||||
Expected volatility |
||||||||
Risk-free interest rate |
||||||||
Expected dividend rate |
January 2, 2022 |
December 31, 2020 |
|||||||
Process equipment |
$ | $ | ||||||
Office equipment |
||||||||
Furniture and fixtures |
||||||||
Leasehold improvements |
||||||||
Construction in progress |
||||||||
|
|
|
|
|||||
Total property and equipment |
||||||||
Less: Accumulated depreciation |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Property and equipment, net |
$ | $ | ||||||
|
|
|
|
Fiscal Year Ended January 2, 2022 |
||||
Operating lease cost |
$ |
Operating leases |
January 2, 2022 |
|||
Weighted-average remaining lease term |
||||
Weighted-average discount rate |
% |
Fiscal Year Ended January 2, 2022 |
||||
Cash paid for amounts included in the measurement of lease liabilities: |
||||
Operating cash flows from operating leases |
$ | |||
Lease liabilities arising from obtaining ROU assets: |
||||
Operating leases |
Operating lease |
||||
2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Thereafter |
||||
|
|
|||
Total |
||||
|
|
|||
Less: imputed interest |
( |
) | ||
|
|
|||
Present value of lease liabilities |
$ | |||
|
|
Operating lease |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
|
|
|||
Total |
$ | |||
|
|
Series |
Authorized |
Issued and Outstanding |
Carrying Value |
Aggregate Liquidation Preference |
||||||||||||
Series A |
$ | $ | ||||||||||||||
Series B |
||||||||||||||||
Series C |
||||||||||||||||
Series D |
||||||||||||||||
Series E |
||||||||||||||||
Series E-2 |
||||||||||||||||
Series F |
||||||||||||||||
Series P-2 |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total Legacy Enovix convertible preferred stock |
$ | $ | ||||||||||||||
|
|
|
|
|
|
|
|
Convertible Preferred Stock Warrants |
Number of Warrants |
Weighted Average Exercise Price |
||||||
Balances as of January 1, 2020 |
$ | |||||||
Granted |
||||||||
Exercised |
— | |||||||
Cancelled |
( |
) | ||||||
Balances as of December 31, 2020 |
$ | |||||||
• | in whole and not in part; |
• | at a price of $ |
• | upon not less than |
• | if, and only if, the last reported sale price of the common stock equals or exceeds $ |
Public Warrants |
Number of Warrants |
Weighted Average Exercise Price |
||||||
Balances as of January 1, 2021 |
$ | |||||||
Assumed through the Business Combination |
||||||||
Exercised |
( |
) | ||||||
Balances as of January 2, 2022 |
$ | |||||||
Exercise of outstanding common stock options |
||||
Options and RSUs available for future grants |
||||
Outstanding restricted stock units for future vesting |
||||
Common stock employee purchase plan |
||||
|
|
|||
|
|
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Cost of revenue |
$ | $ | ||||||
Research and development |
||||||||
Selling, general and administrative |
||||||||
|
|
|
|
|||||
Total stock-based compensation expense |
$ | $ | ||||||
|
|
|
|
Number of Options Outstanding |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life (Years) |
Aggregate Intrinsic Value (1)(2) |
|||||||||||||
Balances as of January 1, 2021 |
$ | |||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | $ | |||||||||||||
Forfeited |
( |
) | ||||||||||||||
|
|
|||||||||||||||
Balances as of January 2, 2022 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Vested and expected to vest at January 2, 2022 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Vested and exercisable at January 2, 2022 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Unvested and exercisable at January 2, 2022 |
$ | $ | ||||||||||||||
|
|
Number of Options Outstanding |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life (Years) |
Aggregate Intrinsic Value (1)(2) |
|||||||||||||
Balances as of January 1, 2020 |
$ | |||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | $ | |||||||||||||
Forfeited/expired |
( |
) | ||||||||||||||
|
|
|||||||||||||||
Balances as of December 31, 2020 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Vested and expected to vest at December 31, 2020 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Vested and exercisable at December 31, 2020 |
$ | $ | ||||||||||||||
|
|
|||||||||||||||
Unvested and exercisable at December 31, 2020 |
$ | $ | ||||||||||||||
|
|
(1) | The aggregate intrinsic value of options exercised is based upon the value of the Company’s stock at exercise. |
(2) | The aggregate intrinsic value of the stock options outstanding as of December 31, 2021 represents the value of the Company’s closing stock price at $ |
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Risk-free interest rate |
% | % | ||||||
Expected term (years) |
||||||||
Dividend yield |
% | % | ||||||
Volatility |
% | % |
Number of Shares Outstanding |
Weighted Average Grant Date Fair Value |
|||||||
Non-vested RSUs Balances as of January 1, 2021 |
$ | |||||||
Granted |
||||||||
Vested |
( |
) | ||||||
Forfeited |
( |
) | ||||||
Non-vested RSUs outstanding as of January 2, 2022 |
$ | |||||||
2021 |
||||
Risk-free interest rate |
% | |||
Expected term (years) |
||||
Dividend yield |
% | |||
Volatility |
% |
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Numerator: |
||||||||
Net loss attributable to common stockholders — basic and diluted |
$ | ( |
) | $ | ( |
) | ||
Denominator: |
||||||||
Weighted-average shares outstanding used in computing net loss per share of common stock, basic and diluted |
||||||||
Net loss per share of common stock: |
||||||||
Basic and diluted |
$ | ( |
) | $ | ( |
) |
As of |
||||||||
January 2, 2022 |
December 31, 2020 |
|||||||
Stock options outstanding |
||||||||
Restricted stock units |
||||||||
Private Placement Warrants |
||||||||
Public Warrants |
||||||||
Employee stock purchase plan estimated shares |
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
United States |
$ | ( |
) | $ | ( |
) | ||
Foreign |
( |
) | ( |
) | ||||
Net loss before income taxes |
$ | ( |
) | $ | ( |
) | ||
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Federal statutory tax rate |
% | % | ||||||
State and local income taxes, net of federal benefit |
% | % | ||||||
Change in fair value of convertible promissory notes |
% | ( |
%) | |||||
Non-deductible convertible preferred stock warrant expense |
( |
%) | ( |
%) | ||||
Federal tax credits |
% | % | ||||||
Share-based compensation |
( |
%) | ( |
%) | ||||
Extinguishment of PPP Loan |
% | % | ||||||
Impact of changes in valuation allowance |
( |
%) | ( |
%) | ||||
Other |
( |
%) | ( |
%) | ||||
Effective tax rate |
% | % | ||||||
January 2, 2022 |
December 31, 2020 |
|||||||
Gross deferred tax assets: |
||||||||
Deferred rent |
$ | $ | ||||||
Lease liabilities |
||||||||
Deferred revenue |
||||||||
Share-based compensation |
||||||||
Federal and state credit carryovers |
||||||||
Federal and state net operating losses |
||||||||
Transaction costs |
||||||||
Depreciation and amortization |
||||||||
Total gross deferred tax assets |
||||||||
Valuation allowance |
( |
) | ( |
) | ||||
Total deferred tax assets, net of valuation allowance |
||||||||
Deferred tax liabilities: |
||||||||
Depreciation and amortization |
( |
) | ||||||
Right-of-use |
( |
) | ||||||
Total deferred tax liabilities |
( |
) | ( |
) | ||||
Net deferred tax assets |
$ | $ | ||||||
Fiscal Years |
||||||||
2021 |
2020 |
|||||||
Balance at beginning of fiscal year |
$ | $ | ||||||
Increases related to current year tax positions |
||||||||
Increases related to the prior year tax positions |
||||||||
|
|
|
|
|||||
Balance at end of fiscal year |
$ | $ | ||||||
|
|
|
|
Amount |
||||
SEC registration fee |
$ | 133,445 | ||
Accountants’ fees and expenses |
100,000 | |||
Legal fees and expenses |
150,000 | |||
Printing fees |
30,000 | |||
Miscellaneous fees and expenses |
36,555 | |||
|
|
|||
Total expenses |
$ | 450,000 | ||
|
|
(1) | In September 2020, RSVAC issued an aggregate of 5,750,000 of common stock to the Sponsor for an aggregate purchase price of $25,000, or approximately $0.004 per share, in connection with RSVA’s organization. |
(2) | In December 2020, RSVAC issued an aggregate of 6,000,000 warrants to the Sponsor at $1.00 per Warrant (for a total purchase price of $6.0 million), with each Warrant exercisable for one share of common stock at an exercise price of $11.50 per share. |
(3) | In July 2021, concurrently with the closing of the Business Combination, the PIPE Investors purchased from us an aggregate of 12,500,000 shares of our Common Stock at a price of $14.00 per share, for an aggregate purchase price equal to $175.0 million. |
(4) | Legacy Enovix granted to certain employees, directors and consultants of it and its subsidiaries, options to purchase an aggregate of 86,098,800 shares of common stock at exercise prices of $0.0092 to $1.87 per share under its 2016 Plan. Of these, options to purchase an aggregate of 29,958,779 shares of Legacy Enovix common stock were outstanding immediately prior to the closing of the Business Combination. Upon the closing of the Business Combination, such options were, automatically and without any required action on the part of any holder or beneficiary thereof, assumed by us and converted into options to purchase an aggregate of 5,530,624 shares of Common Stock at exercise prices of $0.049834 to $10.129291 per share. |
Incorporated by Reference | ||||||||||
Exhibit Number |
Description |
Schedule/ Form |
File No. |
Exhibit |
Filing Date | |||||
10.30 | Administrative Support Agreement, dated December 1, 2020 | 8-K |
001-39753 |
10.4 | December 7, 2020 | |||||
21.1* | List of Subsidiaries | |||||||||
23.1* | Consent of Deloitte and Touche LLP, independent registered public accounting firm | |||||||||
23.2** | Consent of Cooley LLP (included in Exhibit 5.1) | |||||||||
24.1** | Power of Attorney (included on signature page) | |||||||||
101.INS* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document). | |||||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||||
104* | Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments). |
* | Filed herewith. |
** | Previously filed. |
+ | Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. |
# | Indicates a management contract or compensatory plan, contract or arrangement. |
† | Portions of this exhibit, as marked by asterisks, have been omitted in accordance with Regulation S-K Item 601. |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a |
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. |
(5) | That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
ENOVIX CORPORATION |
By: |
/s/ Harrold Rust |
Harrold Rust |
President and Chief Executive Officer |
Signature |
Title |
Date | ||
/s/ Harrold Rust Harrold Rust |
President and Chief Executive Officer and Director (Principal Executive Officer) |
June 14, 2022 | ||
/s/ Steffen Pietzke Steffen Pietzke |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
June 14, 2022 | ||
* Thurman J. Rodgers |
Chairman of the Board | June 14, 2022 | ||
* Betsy Atkins |
Director | June 14, 2022 | ||
Pegah Ebrahimi |
Director | June 14, 2022 | ||
* Emmanuel T. Hernandez |
Director | June 14, 2022 | ||
* John D. McCranie |
Director | June 14, 2022 | ||
* Gregory Reichow |
Director | June 14, 2022 |
* By: |
/s/ Harrold Rust | |
Harrold Rust | ||
Attorney-in-fact |
Exhibit 21.1
ENOVIX CORPORATION
List of Subsidiaries
Subsidiary |
Jurisdiction | |
Enovix Operations Inc. |
Delaware | |
Enovix HoldCo Limited |
Cayman Islands | |
Enovix OpCo Limited |
Cayman Islands | |
Enovix India Holdco LLC |
Delaware |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-258358 on Form S-1 of our report dated March 25, 2022, relating to the consolidated financial statements of Enovix Corporation. We also consent to the reference to us under the heading Experts in such Registration Statement.
/s/ DELOITTE & TOUCHE LLP
San Francisco, California
June 14, 2022